This is evidenced by the fact that the first gene therapy drug for an IRD, Luxturna, an AAV2/2 vector carrying the RPE65 gene for the treatment of RPE65-associated RP or LCA type 2 [139], has recently reached the market. The gene discussed is RPE65; the disease is retinitis pigmentosa 1.